This HCB modulation is similar to that observed by Hsieh et al. [33], who determined that the treatment of human breast cancer cells with di(2-ethylhexyl)phthalate, an environmental pollutant that is a weak agonist of AhR, reduces the antitumor response to doxorubicin due to the increase in CYP3A4 and CYP2C8 expression, which in turn increases the metabolization rate of the drug. Here, AHR is linked to breast carcinoma.